AU2004247468B2 - 2-hydroxymethyl-3,4,5-trihydroxy-1-(4-pentlyoxybenzyl) piperidine as glucosylceramide synthase (GCS) - Google Patents
2-hydroxymethyl-3,4,5-trihydroxy-1-(4-pentlyoxybenzyl) piperidine as glucosylceramide synthase (GCS) Download PDFInfo
- Publication number
- AU2004247468B2 AU2004247468B2 AU2004247468A AU2004247468A AU2004247468B2 AU 2004247468 B2 AU2004247468 B2 AU 2004247468B2 AU 2004247468 A AU2004247468 A AU 2004247468A AU 2004247468 A AU2004247468 A AU 2004247468A AU 2004247468 B2 AU2004247468 B2 AU 2004247468B2
- Authority
- AU
- Australia
- Prior art keywords
- compound
- disease
- administering
- patient
- effective amount
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
- C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/16—Masculine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Reproductive Health (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Communicable Diseases (AREA)
- Psychiatry (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Vascular Medicine (AREA)
- Oncology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0313677.7 | 2003-06-13 | ||
| GBGB0313677.7A GB0313677D0 (en) | 2003-06-13 | 2003-06-13 | Novel compound |
| PCT/GB2004/002450 WO2004111001A1 (en) | 2003-06-13 | 2004-06-09 | 2-hydroxymethyl-3,4,5-trihydroxy-1-(4-pentlyoxybenzyl) piperidine as glucosylceramide synthase (gcs) |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2004247468A1 AU2004247468A1 (en) | 2004-12-23 |
| AU2004247468B2 true AU2004247468B2 (en) | 2009-11-19 |
Family
ID=27590018
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2004247468A Ceased AU2004247468B2 (en) | 2003-06-13 | 2004-06-09 | 2-hydroxymethyl-3,4,5-trihydroxy-1-(4-pentlyoxybenzyl) piperidine as glucosylceramide synthase (GCS) |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US8022219B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP1641755B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP4780784B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN100422150C (cg-RX-API-DMAC7.html) |
| AU (1) | AU2004247468B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BRPI0411293A8 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2528322C (cg-RX-API-DMAC7.html) |
| ES (1) | ES2391634T3 (cg-RX-API-DMAC7.html) |
| GB (1) | GB0313677D0 (cg-RX-API-DMAC7.html) |
| IL (1) | IL172541A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2004111001A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0100889D0 (en) | 2001-01-12 | 2001-02-21 | Oxford Glycosciences Uk Ltd | Compounds |
| ES2393331T3 (es) | 2002-07-17 | 2012-12-20 | Actelion Pharmaceuticals Ltd. | Derivados de piperidintriol como inhibidores de la glucosiliceramida sintasa |
| AU2003248960B2 (en) | 2002-07-17 | 2009-06-25 | Idorsia Pharmaceuticals Ltd | Piperidinetriol derivatives as inhibitors of glycosylceramidsynthase |
| GB0313677D0 (en) | 2003-06-13 | 2003-07-16 | Oxford Glycosciences Uk Ltd | Novel compound |
| GB0313678D0 (en) * | 2003-06-13 | 2003-07-16 | Oxford Glycosciences Uk Ltd | Novel compounds |
| JP5047941B2 (ja) | 2005-03-23 | 2012-10-10 | アクテリオン ファーマシューティカルズ リミテッド | 免疫調節物質としての水素付加されたベンゾ(c)チオフェン誘導体 |
| US20140350049A1 (en) | 2011-11-29 | 2014-11-27 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods and pharmaceutical compositions for the treatment of darier disease |
| CN108700594B (zh) | 2015-11-18 | 2021-06-29 | 建新公司 | 多囊性肾病的生物标志物及其用途 |
| WO2020193746A1 (en) | 2019-03-28 | 2020-10-01 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for predicting the survival of patients suffering from melanoma |
| US12612380B2 (en) | 2019-05-10 | 2026-04-28 | Alectos Therapeutics 1Nc | Non-lysosomal glucosylceramidase inhibitors and uses thereof |
| PE20231423A1 (es) | 2020-05-07 | 2023-09-13 | Alectos Therapeutics Inc | Inhibidores de glucosilceramidasa no lisosomal y los usos de los mismos |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002055498A1 (en) * | 2001-01-12 | 2002-07-18 | Oxford Glycosciences (Uk) Ltd | Pharmaceutically active piperidine derivatives |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NO154918C (no) | 1977-08-27 | 1987-01-14 | Bayer Ag | Analogifremgangsmaate til fremstilling av terapeutisk aktive derivater av 3,4,5-trihydroksypiperidin. |
| DE3007078A1 (de) | 1980-02-26 | 1981-09-10 | Bayer Ag, 5090 Leverkusen | Neue derivate von 3,4,5-trihydroxypiperidin, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel sowie in der tierernaehrung |
| DE3024901A1 (de) | 1980-07-01 | 1982-01-28 | Bayer Ag, 5090 Leverkusen | Herbizide mittel auf basis von piperidin-derivaten |
| DE3247615A1 (de) | 1982-12-23 | 1984-07-05 | Hoechst Ag, 6230 Frankfurt | Substituierte phenylsulfonyloxybenzimidazolcarbaminate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel |
| DE3737523A1 (de) | 1987-11-05 | 1989-05-18 | Bayer Ag | Verwendung von substituierten hydroxypiperidinen als antivirale mittel |
| US5003072A (en) | 1988-11-03 | 1991-03-26 | G. D. Searle & Co. | 1,5-dideoxy-1,5-imino-D-glucitol derivatives |
| JPH02306962A (ja) | 1989-05-19 | 1990-12-20 | Meiji Seika Kaisha Ltd | 新規n―置換―1―デオキシノジリマイシン誘導体及びそれを含有する癌細胞転移抑制剤 |
| JPH0324057A (ja) | 1989-06-22 | 1991-02-01 | Tosoh Corp | ポリヒドロキシピペリジン類及びその製造法 |
| WO1991003242A1 (en) | 1989-09-07 | 1991-03-21 | Nippon Shinyaku Co., Ltd. | Antiviral drug |
| EP0536402A4 (en) | 1990-06-29 | 1993-05-12 | Nippon Shinyaku Company, Limited | Piperidine derivative |
| US5276120A (en) | 1991-05-30 | 1994-01-04 | The Scripps Research Institute | Process for forming omega-deuxy-azasugars |
| JP3506434B2 (ja) | 1993-05-05 | 2004-03-15 | ロシュ ダイアグノスティックス ゲーエムベーハー | ブレビバクテリウム・ステロリカム由来のコレステロールオキシダーゼ |
| US5798366A (en) | 1993-05-13 | 1998-08-25 | Monsanto Company | Method for treatment of CNS-involved lysosomal storage diseases |
| US6291657B1 (en) | 1993-05-13 | 2001-09-18 | Monsanto Company | Deoxygalactonojirimycin derivatives |
| US5451679A (en) * | 1994-03-08 | 1995-09-19 | G. D. Searle & Co. | 2-chloro and 2-bromo derivatives of 1,5-iminosugars |
| US6177447B1 (en) | 1996-07-15 | 2001-01-23 | Universiteit Van Amsterdam | Deoxynojirimycin derivatives and their uses as glucosylceramidase inhibitors |
| IL132170A0 (en) | 1997-05-06 | 2001-03-19 | Novo Nordisk As | Novel heterocyclic compounds |
| WO1999001555A1 (en) | 1997-07-03 | 1999-01-14 | The United States Of America Represented By The Secretary, Department Of Health And Human Services | Genes for niemann-pick type c disease |
| JP2001522833A (ja) | 1997-11-10 | 2001-11-20 | ジー・ディー・サール・アンド・カンパニー | 多剤耐性を治療するためのアルキル化イミノ糖類の使用 |
| US6610703B1 (en) | 1998-12-10 | 2003-08-26 | G.D. Searle & Co. | Method for treatment of glycolipid storage diseases |
| WO2000056334A1 (en) | 1999-03-19 | 2000-09-28 | The Trustees Of Boston College | Use of imino sugars for anti-tumor therapy |
| GB9909064D0 (en) | 1999-04-20 | 1999-06-16 | Oxford Glycosciences Uk Ltd | Therapies |
| JP2003505430A (ja) | 1999-07-26 | 2003-02-12 | ジー・ディー・サール・アンド・カンパニー | デオキシノジリマイシンの長鎖n−アルキル誘導体およびグルコセレブロシダーゼ酵素の糖脂質異常蓄積疾患の治療用の薬剤の製造のための使用 |
| DE60037664T2 (de) | 1999-08-10 | 2008-12-24 | The Chancellor, Masters And Scholars Of The University Of Oxford | Langkettige n-alkyl verbindungen und deren oxa-derivate zur verwendung als anitvirale mittel |
| US7256005B2 (en) | 1999-08-10 | 2007-08-14 | The Chancellor, Masters And Scholars Of The University Of Oxford | Methods for identifying iminosugar derivatives that inhibit HCV p7 ion channel activity |
| WO2002055489A2 (en) | 2000-12-27 | 2002-07-18 | Univ Columbia | Pim kinase-related methods |
| DE60308378T2 (de) | 2002-03-13 | 2007-09-20 | Unither Pharmaceuticals, Inc. | Nicht-Hormonal Verfahren zur männlichen Verhütung |
| AU2003248960B2 (en) * | 2002-07-17 | 2009-06-25 | Idorsia Pharmaceuticals Ltd | Piperidinetriol derivatives as inhibitors of glycosylceramidsynthase |
| ES2393331T3 (es) | 2002-07-17 | 2012-12-20 | Actelion Pharmaceuticals Ltd. | Derivados de piperidintriol como inhibidores de la glucosiliceramida sintasa |
| GB0313678D0 (en) * | 2003-06-13 | 2003-07-16 | Oxford Glycosciences Uk Ltd | Novel compounds |
| GB0313677D0 (en) | 2003-06-13 | 2003-07-16 | Oxford Glycosciences Uk Ltd | Novel compound |
| GB0400812D0 (en) | 2004-01-14 | 2004-02-18 | Celltech R&D Ltd | Novel compounds |
-
2003
- 2003-06-13 GB GBGB0313677.7A patent/GB0313677D0/en not_active Ceased
-
2004
- 2004-06-09 AU AU2004247468A patent/AU2004247468B2/en not_active Ceased
- 2004-06-09 CN CNB2004800162994A patent/CN100422150C/zh not_active Expired - Fee Related
- 2004-06-09 JP JP2006516390A patent/JP4780784B2/ja not_active Expired - Fee Related
- 2004-06-09 EP EP04736421A patent/EP1641755B1/en not_active Expired - Lifetime
- 2004-06-09 ES ES04736421T patent/ES2391634T3/es not_active Expired - Lifetime
- 2004-06-09 WO PCT/GB2004/002450 patent/WO2004111001A1/en not_active Ceased
- 2004-06-09 BR BRPI0411293A patent/BRPI0411293A8/pt not_active Application Discontinuation
- 2004-06-09 US US10/560,383 patent/US8022219B2/en not_active Expired - Fee Related
- 2004-06-09 CA CA2528322A patent/CA2528322C/en not_active Expired - Fee Related
-
2005
- 2005-12-13 IL IL172541A patent/IL172541A/en active IP Right Grant
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002055498A1 (en) * | 2001-01-12 | 2002-07-18 | Oxford Glycosciences (Uk) Ltd | Pharmaceutically active piperidine derivatives |
Also Published As
| Publication number | Publication date |
|---|---|
| US8022219B2 (en) | 2011-09-20 |
| WO2004111001A1 (en) | 2004-12-23 |
| ES2391634T3 (es) | 2012-11-28 |
| CA2528322C (en) | 2012-07-31 |
| BRPI0411293A (pt) | 2006-08-29 |
| AU2004247468A1 (en) | 2004-12-23 |
| EP1641755A1 (en) | 2006-04-05 |
| IL172541A0 (en) | 2006-04-10 |
| GB0313677D0 (en) | 2003-07-16 |
| EP1641755B1 (en) | 2012-08-15 |
| IL172541A (en) | 2011-07-31 |
| JP2006527252A (ja) | 2006-11-30 |
| CN1805934A (zh) | 2006-07-19 |
| BRPI0411293A8 (pt) | 2017-12-26 |
| CA2528322A1 (en) | 2004-12-23 |
| US20070259918A1 (en) | 2007-11-08 |
| CN100422150C (zh) | 2008-10-01 |
| JP4780784B2 (ja) | 2011-09-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20080234324A1 (en) | Piperidine Derivatives as Gcs Inhibitors | |
| US8729099B2 (en) | Pharmaceutically active piperidine derivatives | |
| US7985760B2 (en) | Piperidinetriol derivatives as inhibitors of glycosyceramid synthase | |
| AU2002219363A1 (en) | Pharmaceutically active piperidine derivatives | |
| AU2004247469B2 (en) | 2-hydroxymethyl-3,4,5-trihydroxy-1-benzilpiperidine derivatives as inhibitors of glucosylceramide | |
| US7994198B2 (en) | Piperidinetriol derivatives as inhibitors of glycosylceramidsynthase | |
| EP1641755B1 (en) | 2-hydroxymethyl-3,4,5-trihydroxy-1-(4-pentlyoxybenzyl)piperidine as glucosylceramide synthase (gcs) inhibitor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) | ||
| PC | Assignment registered |
Owner name: IDORSIA PHARMACEUTICALS LTD Free format text: FORMER OWNER(S): ACTELION PHARMACEUTICALS LTD |
|
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |